Background: The Daclatasvir and Sofosbuvir combination therapy (SOF/DCV) has
| INTRODUCTION
Globally, hepatitis C virus (HCV) is a major cause of morbidity and mortality, infecting an estimated 170 million persons. 1 Successful treatment results in curing HCV, which has been linked to significant reductions in the risk of HCV-related complications including liver failure, hepatocellular carcinoma (HCC), and death. weight-based RBV. 5 DCV plus SOF was associated with high rates of sustained virological response (SVR) among patients with previously known to be associated with a poor response. Impressively, this regimen was highly efficient in "difficult to cure" patients. 6 The present observational study designed to evaluate the effectiveness, safety, tolerability, of DCV plus SOF with or without RBV in treatment HCV-related liver cirrhosis in the real world.
2 | ME TH ODS respectively; P < .01; P < .001; P < .004; P < .02; P < .003, respectively; Table 4 ).
| Safety and tolerability
Side effects were listed in (Figure 2) . The most common adverse events were anaemia (3% and 31.3%); photosensitivity (0% and 4%); hyperbilirubinemia (5% and 39%); pruritus (2% and 17%); fatigue Results from clinical studies demonstrate that the combination of SOF and DCV, with once-daily oral dosing, a low pill burden, good tolerability, and limited drug-drug interactions, in addition to high (90%) SVR rates. 10 Our study is one of the largest reports to date using anti-viral regimen to treat patients had genotype 4 HCV infection and liver cirrhosis. The rates of SVR 12 were high in both naive cirrhotic patients (94%) and 90.4% in previous treated patients.
Cirrhotic patients have a priority for treatment despite significant lower SVR. Consistent with previous studies, the SVR12 rate was lower in patients with Child-Pugh C, 11 advanced liver disease such as low platelet count or low albumin level were associated with increased risk of tretment failure. However, much of this difference was related to pre-existing advanced liver disease rather than to inadequate virological efficacy.
T A B L E 2 Virologic response in naive patients
Efficacy outcomes are consistent with results of phase III studies of this regimen (ALLY programme), despite the high proportion of patients with advanced disease. represented 17% of their study population, and showed lower SVR compared with noncirrhotic (78% vs 93%). 12 Also in a previous phase III study of genotype 3 infection, SVR12 was achieved by 96% of patients without cirrhosis but by only 63% of patients with cirrhosis after 12 weeks of treatment with DCV+SOF. 13 Virological failure was infrequent, occurring in 42 patients (8%)
overall. Thirty two (6%) were non responders; and 10 (2%) cases were relapsers. Thirty-one patients (7%) were CTP-A and 11 (13.3%) patients were CTP-B. Cirrhotic patients who failed to achieve SVR12
were associated with advanced liver disease that was present at start of treatment. However, most patients with advanced liver disease completed the programme successfully. This finding consistent with other studies that confirmed HCV suppression is not always capable of arresting clinical deterioration in patients with very advanced disease. 14 Severity of liver disease at baseline had a significant impact on SVR12. Patients low MELD score, low liver stiffness (<20 kPa) and high platelets count, at time of treatment were more likely to achieve SVR12. Bashar reported that patients with lower MELD score at time of treatment initiation were more likely to achieve SVR12 (<0.018).
Pre-treatment MELD was strongly associated with relapse rate. 15 Our analysis showed that SVR12 rates were increased by addition of RBV (<0.003). Consistent with other studies, addition of RBV to the regimen for 12 or 16 weeks increased SVR12 rates to 83%
and 89%, respectively, in patients with advanced fibrosis or compensated cirrhosis. 16 The results of a French expanded access programme support this interpretation. Virological failure for all treated patients including for those who were lost to follow-up and discontinuation due to adverse effect. Overall, DCV+SOF with or without RBV was well tolerated, our study also showed mild side effect rate in this difficult patient population, which is likely related to underlying liver disease rather to the drugs used.
In summary, the SOF/DCV combination at their standard doses is associated with a high rate of SVR12 in chronic HCV patients irrespective of past treatment-experience or baseline HCV RNA levels.
Combination with RBV increases the SVR rate. DCV/SOF-RBV represents an important option for HCV genotype 4-infected patients with advanced liver disease.
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